Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Share-based Compensation (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Share-based Compensation for 7 consecutive years, with $8.1 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 36.84% to $8.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.6 million through Dec 2025, down 27.25% year-over-year, with the annual reading at $37.6 million for FY2025, 27.25% down from the prior year.
  • Share-based Compensation hit $8.1 million in Q4 2025 for Allogene Therapeutics, down from $8.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $22.9 million in Q2 2022 to a low of $8.1 million in Q4 2025.
  • Historically, Share-based Compensation has averaged $16.0 million across 5 years, with a median of $16.0 million in 2023.
  • Biggest five-year swings in Share-based Compensation: surged 33.93% in 2021 and later tumbled 36.84% in 2025.
  • Year by year, Share-based Compensation stood at $22.0 million in 2021, then fell by 21.74% to $17.2 million in 2022, then fell by 11.67% to $15.2 million in 2023, then dropped by 15.49% to $12.9 million in 2024, then plummeted by 36.84% to $8.1 million in 2025.
  • Business Quant data shows Share-based Compensation for ALLO at $8.1 million in Q4 2025, $8.7 million in Q3 2025, and $8.7 million in Q2 2025.